research Transient Efficacy of Tofacitinib in Alopecia Areata Universalis
Tofacitinib temporarily regrew hair in a man with alopecia, but its effects didn't last.
Search
for
Sort by
Research
450-480 / 1000+ results research Epidermal Growth Factor Receptor Inhibitors: A Review of Cutaneous Adverse Events and Management
Skin side effects from cancer drugs targeting EGFR can affect treatment adherence but can be managed with antibiotics like tetracycline.
research 27604 Response to baricitinib in the treatment of patients with early and late onset alopecia areata in the phase 2 portion of BRAVE-AA1 randomized controlled trial
Baricitinib was effective in treating both early and late onset alopecia areata.
research Administration of dutasteride in animal models of retinitis pigmentosa
Dutasteride potentially improves cell survival and reduces retinal damage in retinitis pigmentosa.
research A retrospective study of oral tofacitinib therapy for alopecia areata
research Management of Cutaneous and Extracutaneous Side Effects of Smoothened Inhibitor Therapy for Advanced Basal Cell Carcinoma
The document concludes that side effects from Smoothened inhibitor drugs for skin cancer are reversible and can be managed with a team approach to maintain quality of life.
research 576 INTASYL PH-762: Intratumoral immunotherapy targeting PD-1
PH-762 shows promise in treating skin cancer by effectively targeting and silencing PD-1 in tumors with minimal side effects.
research Real-World Ritlecitinib Treatment of Severe Alopecia Areata (AA) in the US: Patient Characteristics and Physician Satisfaction
Ritlecitinib effectively improves hair regrowth and physician satisfaction in severe alopecia areata over time.
research THE USE OF TOFACITINIB IN THE TREATMENT OF IMMUNE-MEDIATED UNIVERSAL ALOPECIA IN A PATIENT WITH SYSTEMIC LUPUS ERYTHEMATOSUS: A CASE REPORT
Tofacitinib improved arthritis and partially improved hair loss in a lupus patient without side effects.
research Treatment of postmenopausal frontal fibrosing alopecia with oral dutasteride
Oral dutasteride can potentially treat frontal fibrosing alopecia in postmenopausal women, with some patients showing disease arrest and hair regrowth.
research Enhancement of Intermittent Androgen Ablation Therapy by Finasteride Administration in Animal Models
Finasteride may improve prostate cancer therapy by enhancing testosterone's benefits and reducing risks.
research Ritlecitinib for Severe Alopecia Areata: A 24-Week, Multicentre, Real-World Study
In a 24-week multicentre study in Italy, ritlecitinib 50 mg/day was tested on 102 patients aged 12 and older with severe alopecia areata. The study found that 40.2% of patients experienced significant hair regrowth, with adolescents responding better (48.6%) than adults (21.9%). The mean Severity of Alopecia Tool (SALT) score improved from 86.2 to 40.8, and improvements were noted in trichoscopic signs, quality of life, and hair regrowth on eyebrows, eyelashes, and nails. The treatment was generally well tolerated, with mild adverse events like acne and headache, and only one severe case of anaemia. Overall, ritlecitinib was effective and safe, particularly for adolescents.
research Sublingual tofacitinib for alopecia areata: a roll‐over pilot clinical trial and analysis of pharmacokinetics
The trial showed that a new under-the-tongue treatment for severe hair loss was somewhat effective in a small group of people.
research Finasteride and dutasteride may reduce melanoma risk
Finasteride and dutasteride might lower melanoma risk.
research Fulvestrant, a new treatment option for advanced breast cancer: tolerability versus existing agents
Fulvestrant is a well-tolerated new treatment for advanced breast cancer that may delay chemotherapy.
research Analyzing the role of tofacitinib in treatment of alopecia areata: A retrospective analysis from a tertiary care center of North India
Tofacitinib effectively reduced hair loss in alopecia areata patients without adverse effects.
research CUTANEOUS T-CELL LYMPHOMA
The document concludes that DAB389-IL2 is promising for treating refractory cutaneous T-cell lymphoma, but more research is needed on its effectiveness and side effect management.
research Use of natural molecules as anti-angiogenic inhibitors for vascular endothelial growth factor receptor
Curcumin, EGCG, barringtozenol, and finasteride are effective VEGFR inhibitors.
research Patient Profile and Treatment Characteristics of Early Ritlecitinib Initiators in the US
Ritlecitinib provides new treatment options for diverse alopecia areata patients.
research Efficacy and safety of tofacitinib in patients with alopecia areata
Tofacitinib helps hair regrowth in alopecia areata but relapse is common after stopping treatment.
research 42004 Scalp, eyebrow, and eyelash hair regrowth with continued ritlecitinib treatment among patients with alopecia areata without target efficacy response at Week 24: post hoc analysis of the ALLEGRO phase 2b/3 study
Continued ritlecitinib treatment can lead to hair regrowth in some patients with alopecia areata who initially don't respond.
research Editor's evaluation: Crosstalk with keratinocytes causes GNAQ oncogene specificity in melanoma
Keratinocytes can reduce the survival of certain melanoma cells, suggesting new therapy paths.
research Efficacy and patient-reported outcomes in advanced non-small cell lung cancer patients receiving aumolertinib as first-line therapy: a real-world study
Aumolertinib effectively controls lung cancer and improves quality of life.
research Neoadjuvant therapy with Disitamab vedotin in treating muscle-invasive bladder cancer: A case report
Disitamab vedotin and gemcitabine effectively treated bladder cancer without major side effects.
research Upadacitinib for the treatment of alopecia areata – A case report
Upadacitinib helped regrow hair in a severe alopecia areata patient but stopping treatment caused hair loss to return.
research Upadacitinib for the treatment of alopecia areata and severe atopic dermatitis in a paediatric patient: A case report
Upadacitinib successfully treated a child's severe skin and hair loss issues.
research Reply to: “Tofacitinib for the treatment of severe alopecia areata and variants”
More extensive trials are needed to understand tofacitinib's role in treating severe hair loss.
research Efficacy and Safety of Ritlecitinib in Alopecia Areata: A Systematic Review and Meta-Analysis (Preprint)
Ritlecitinib improves hair regrowth in alopecia areata without increasing adverse risks.
research Using patient preference to inform ritlecitinib dose selection for alopecia areata treatment
Patients prefer the higher 50 mg dose of ritlecitinib for better hair regrowth despite higher risks.
research AP-1 and TGFß cooperativity drives non-canonical Hedgehog signaling in resistant basal cell carcinoma
AP-1 and TGFß work together to drive resistance in basal cell carcinoma, suggesting new treatment options.